Abeona Therapeutics (ABEO) legal chief sells 13,578 shares

Rhea-AI Filing Summary

Abeona Therapeutics SVP and Chief Legal Officer Brendan M. O'Malley reported a sale of company stock. On January 22, 2026, he sold 13,578 shares of common stock at a weighted average price of $5.3309 per share. According to the filing, the sale was made to cover tax obligations associated with the vesting of restricted stock awards, meaning it was tied to equity compensation rather than an open-market discretionary sale of his full holdings. After this transaction, O'Malley beneficially owned 451,134 shares of Abeona common stock directly.

Insider Trade Summary

Net Seller: 13,578 shares ($72,383)

Net Sell 1 txn

Insider O'Malley Brendan M.

Role SVP, Chief Legal Officer

Sold 13,578 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,578	$5.3309	$72K

Holdings After Transaction: Common Stock — 451,134 shares (Direct)

Footnotes (1)

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		13,578	D	$5.3309(2)	451,134	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.33 to $5.38 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Brendan O'Malley	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading ABEO stock in this Form 4 filing?

The Form 4 reports activity by Brendan M. O'Malley, who serves as SVP and Chief Legal Officer of Abeona Therapeutics Inc. (ABEO).

How many Abeona Therapeutics (ABEO) shares did Brendan O'Malley sell?

Brendan O'Malley sold 13,578 shares of Abeona Therapeutics common stock in a transaction dated January 22, 2026.

At what price were the ABEO shares sold in this insider transaction?

The filing reports a weighted average sale price of $5.3309 per share, with multiple trades executed at prices ranging from $5.33 to $5.38 inclusive.

Why did Abeona Therapeutics insider Brendan O'Malley sell shares?

The footnotes state that the sale was made to cover tax obligations associated with the vesting of restricted stock awards, indicating it was related to equity compensation.

How many ABEO shares does Brendan O'Malley hold after this Form 4 transaction?

Following the reported sale, Brendan O'Malley beneficially owned 451,134 shares of Abeona Therapeutics common stock, held in direct ownership.

Does the Form 4 indicate indirect ownership or third-party entities for these ABEO shares?

The transaction is reported as direct (D) ownership, and the footnotes describe tax-related sales and pricing details without mentioning any separate entities holding the shares.